Pseudomonas aeruginosa (Pa) is one of the most common and clinically important pathogens in patients with cystic fibrosis (CF). Chronic Pa colonization in CF patients is associated with increased morbidity and mortality. Pa strains causing early infection are usually antibiotic sensitive and have low bacterial density in the airways. As a result, the treatment strategy has shifted from suppressive therapy in patients chronically colonized by Pa to attempts at early eradication therapy as soon as Pa is detected. In the literature, different treatment regimens have been studied. However, the optimal treatment regimen and duration of treatment are not yet determined.
Introduction
Pseudomonas aeruginosa (Pa) is one of the major pulmonary pathogens in patients with cystic fibrosis (CF). By adulthood, 80% of the patients are colonized by Pa [1] .
The first Pa colonization episode can occur very early in life. After a first ever colonization episode, patients may go through different episodes of colonization (intermittent colonization), preceding chronic colonization by months to years, eventually resulting in chronic infection [2] [3] [4] . Pa strains causing early colonization have usually a nonmucoid phenotype, whereas Pa strains in chronically colonized patients are mucoid and form biofilms.
Interesting data on the natural history of acquisition of Pa and evolution from nonmucoid to mucoid Pa come from follow-up of CF patients detected through neonatal screening projects: Li and co-workers [5] prospectively evaluated 56 CF patients, diagnosed by the Wisconsin CF Neonatal Screening Project. Nearly one third (29%) acquired nonmucoid Pa already in the first 6 months of life. Nonmucoid Pa was acquired at a median age of 1 year and mucoid Pa at a median age of 13 years.
Without antibiotic treatment for initial Pa colonization, approximately 20% of the CF patients will become chronically colonized directly after the first positive culture. The remainder develops chronic colonization after a median time of 12 months [6] .
Unfortunately, comparison of the different studies on (chronic) colonization by Pa is hampered by the lack of agreement on the definitions of chronic colonization/infection. Currently, there is no universally accepted definition and both terms are often used equivalently in the literature. An overview of the different criteria is presented in Table 1 . Most European CF centers use the "European consensus criteria" agreed by Döring et al. [7] or the "Leeds criteria" defined by Lee et al. [8] .
Pa lung colonization in CF patients clearly results in a poorer clinical outcome, especially when chronically colonized [9] [10] [11] [12] . Acquisition of mucoid Pa is associated with an accelerated rate of decline in pulmonary function [13] .
Pa strains causing early colonization are usually antibiotic sensitive and have low bacterial density in the airways [2, 4] . Aggressive antibiotic treatment of these early infecting strains often successfully eradicates Pa. As a result, treatment strategy has shifted from suppressive therapy in patients chronically colonized by Pa to attempts at early eradication therapy as soon as Pa is detected [14, 15] .
Eradication therapy for Pa colonization episodes in not chronically colonized CF patients
The first observations of the favorable effect of eradication treatment for early Pa isolates date from the eighties and early nineties.
Littlewood et al. [19] observed that treatment with inhaled colistin in 7 patients with recent Pa acquisition resulted in a significant reduction of Pa positive cultures.
Steinkamp et al. [20] treated 28 CF children with recent Pa colonization with IV anti-pseudomonas antibiotics during 2 weeks. Eighteen (64%) of these patients were free of Pa at the end of the treatment period. This number gradually declined over time, leaving just 1 patient (3.5%) free of Pa after 15 months. Valerius et al. [21] compared treatment with oral ciprofloxacin and inhaled colistin for 3 weeks with placebo for 3 weeks in 26 CF patients with a new Pa colonization episode. At the end of the 27 month observation period, the treatment group had significantly less Pa positive cultures and a significantly lower rate of chronic colonization.
As a result of these observations, several eradication trials, studying different treatment regimens, have been undertaken.
Initially, the combination of oral ciprofloxacin and inhaled antibiotics (tobramycin or colistin) for varying time was most frequently used. The more recent studies also report the value of inhaled antibiotics (mainly tobramycin) for early eradication.
However, comparison between the different studies is difficult due to different methodologies, different eradication treatment regimens, different outcome measures and different definitions of eradication and chronic colonization and/or chronic infection.
In the following section, we will discuss both microbiological and clinical endpoints of the eradication studies and also focus on head to head comparative data of treatment regimens. The topics of eradication of mucoid Pa and genotype based eradication studies will also be addressed. All eradication trials are summarized in Table 2 . More extensive data from the eradication trials are available online in Table 3 . Table 1 An overview of the different definitions of (chronic) P. aeruginosa colonization/infection. European consensus criteria [7] • Lung colonization by Pa: "Presence of Pa in the bronchial tree without direct (inflammation, fever, etc.) or indirect (specific antibody response) signs of infection and tissue damage" • Chronic lung colonization by Pa: "Presence of Pa in the bronchial tree for at least 6 months, based on at least three positive cultures with at least one month intervals between them without direct (inflammation, fever, etc.) or indirect (specific antibody response) signs of infection and tissue damage".
• Lung infection by Pa: "Presence of Pa in the bronchial tree with direct (inflammation, fever, etc.) or indirect (specific antibody response) signs of infection and tissue damage. Infection can also be diagnosed on the basis of a positive antibody response in at least two examinations for patients who do not expectorate and present with negative bacterial cultures".
• Chronic lung infection by Pa: "Presence of Pa in the bronchial tree for at least 6 months, based on at least three positive cultures with at least one month intervals between them with direct (inflammation, fever, etc.) or indirect (specific antibody response) signs of infection and tissue damage. Chronic infection can also be diagnosed on the basis of a positive antibody response in at least two examinations for patients who do not expectorate and present with negative bacterial cultures."
The Leeds criteria [8] classify CF patients as:
• Never infected by Pa: Pa has never been cultured from sputum or cough swab. According to Ballmann et al. [17] and Kerem et al. [10] a patient is considered chronically infected by Pa when having more than 50% of cough swabs or sputum samples positive in a 12-month period. Fitzsimmons et al. [18] classified a patient as chronically infected if the last sputum sample of each year grows Pa. 
Early eradication trials with microbiologic endpoints
• Studies on microbiological effect: eradication, recurrence of Pa and time to recurrence Whatever early eradication treatment is used, all trials report successful eradication and/or significantly less Pa positive cultures during treatment [19, [21] [22] [23] . The more recent eradication trials (2000-2012) also report percentages of eradication immediately after or within 6 months after treatment, the majority varying between 80% and 100% [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , except for Nixon et al. (25% eradication) [9] and Taccetti et al. (65% eradication) [36] . In 12% [31] to 100% [29] of the patients Pa recurs after a median time period from 7.5 to 26 months.
• Studies on delay in chronic infection
The Danish group reported that only 12 of the 99 patients (12%) with a first ever Pa isolate developed chronic infection after a median time of 3.7 years, compared to 72% of the historic control patients. Up to 80% of the patients were protected against development of chronic infection for up to 15 years, according to the Kaplan-Meier estimate [37, 38] .
Early eradication trials with clinical endpoints
In view of the deleterious effect of chronic Pa on the clinical outcome of CF patients, it seems logical that preventing or delaying chronic infection should have an advantageous effect on clinical parameters. However, data on the effect of eradication therapy on clinical parameters are currently scarce. This may be due to the short observation time in most studies. Steinkamp et al. [20] reported a significantly better weight gain immediately after intravenous antibiotic treatment.
Frederiksen et al. [37] demonstrated a favorable effect on lung function parameters, whereas others [20, 23, 30, 34] did not. Recently, Mayer-Hamblett [35] and colleagues demonstrated that the children included in the EPIC trial who failed to eradicate Pa after initial antibiotic treatment are at higher risk of subsequent exacerbation, suggesting clinical benefit of a successful early Pa eradication.
Head-to-head comparison of different treatment regimens
Up till now, only 4 studies compared the efficacy of different treatment strategies/treatment duration for eradication of Pa. None of them detected a statistically significant difference in eradication [32] [33] [34] 36] .
It is worth noting that the Danish group changed their early treatment policy to a 3 month instead of a 3 week antibiotic treatment after noticing a (statistically not significant) trend to longer Pa free time period in the 3 month treatment strategy [38] .
Is eradication of mucoid Pa strains possible?
It is often stated that mucoid strains of Pa cannot be eliminated from the lower airways. However, recent studies contradict this theorem. Gibson et al. [25] reported eradication of both nonmucoid and mucoid Pa with inhaled tobramycin. In a UKbased study [39] , 57.8% of the patients with mucoid Pa cleared this organism for more than 1 year and 32.8% remained Pa free for a median time of 55 months after antibiotic treatment. Recently, Troxler et al. [40] observed clearance of mucoid Pa in 73.3% of patients undergoing eradication attempt, compared to only 36.6% of the non-treated patients (p b 0.05).
Does early eradication treatment result in eradication or suppression of Pa?
This question on eradication versus suppression can only be answered by studying the initial Pa genotypes and comparing them with the genotypes of subsequent Pa isolates. These data however are scarce and provide conflicting results.
Whereas in some studies the majority of the patients are colonized by a genetically different strain in subsequent Pa colonization episodes [29, 36] , suggesting that eradication therapy really eradicated the initial Pa, others revealed the opposite [26, 28, 34] . The latter studies suggest that Pa recurrence is caused by a regrowth of partially suppressed Pa or by acquisition from the same (environmental?) source.
Discussion
Since the first reports on the advantageous effect of early antibiotic treatment for Pa colonization episodes in not chronically colonized patients, several "early eradication studies" have been carried out. The majority of these studies report an 80 to 100% eradication success rate with a median time to Pa recurrence of 7.5 to 26 months. Moreover, the Danish data demonstrated that early eradication therapy postpones the onset of chronic colonization. Although previously considered to be impossible, recent reports showed that mucoid Pa can also be eradicated from the CF airways. Relying on these observations and trials, the use of eradication treatment for Pa in not chronically colonized/infected patients has become common clinical practice. Nevertheless, questions remain on the optimal way of administration of antibiotics (intravenous/oral/inhalation or combinations) and the optimal treatment duration for long lasting eradication.
There is no significant evidence that IV treatment is the optimal treatment regimen. Although Munck et al. reported a 100% eradication after intravenous antipseudomonal treatment, all patients reacquired Pa after a median time of 8 months. The less successful eradication results of Nixon et al. [9] can presumably be explained by late diagnosis using annual BAL for detection and by the high number of mucoid Pa. The late onset of IV treatment (1-11 months, median time 5 months after detection of Pa) in the study of Steinkamp et al. [20] might have negatively affected the eradication success.
Comparative studies have not defined a superior treatment option until now, neither has a longer or combination treatment period proven to be superior. This fact is also important from the patient's point of view: a reduced treatment intensity possibly enhances treatment adherence and diminishes the risk of drug toxicity. In the ELITE trial, treatment with inhaled tobramycin during 56 days was not superior to 28 days. In the EPIC trial combined treatment of oral ciprofloxacin and inhaled tobramycin was not more effective than monotherapy with inhaled tobramycin. Adding oral ciprofloxacin during a 2-week period might probably be too short to detect any differences. In the "Danish experience", using oral ciprofloxacin and inhaled colistin, a non-significant trend for a prolonged Pa free period was observed in 3 months (10.4 months) compared to the 3 week regimen (5 months). Nevertheless, this observation led to a change in early treatment policy favoring a 3 month regimen [38] . The open study of Proesmans and colleagues [32] compared two widely used but totally different eradication schedules (inhaled tobramycin during 28 days versus oral ciprofloxacin and inhaled colistin for 3months). No statistical differences in eradication neither in recurrence of positive cultures could be detected. Unfortunately, the study was underpowered.
Another unanswered question is whether antibiotic therapy really eradicates the initial Pa or only results in a temporary reduction of the bacterial load, escaping the sensitivity of the detection techniques. This question on eradication versus suppression can only be addressed by studying the initial Pa genotype and comparing this with the genotype of subsequent Pa isolates. A few studies, addressing this topic, provide conflicting results with 25 to 75% of the patients being colonized by an identical genotype in a subsequent colonization episode after what initially was considered a successful eradication. Moreover, the presence of an identical Pa isolate in a subsequent Pa colonization episode proved to be an ominous sign for impending chronic colonization [28] . Genotyping of Pa is essential in the evaluation of the efficacy of eradication treatment and should be included in each future eradication trial.
Remarkably, a similar rate of eradication failures (10-20%) is noticed in many clinical studies with widely varying schedules of antipseudomonal antibiotics. This can partially be explained by the different inclusion criteria (first ever versus previous Pa), different methodology, different definitions of eradication and/or Pa free time period and different follow-up times, the latter especially influencing recurrence rates. Even when only considering eradication results for a first ever Pa episode, no 100% eradication is achieved. Patient factors possibly contributing to eradication failure include therapy compliance, delay in detection of Pa (in most centers only quarterly respiratory cultures are taken) and the use of insensitive detection methods (culture on oral swabs or nasopharyngeal aspirates used in young, non sputum expectorating children with first Pa colonization episodes). Furthermore, the hypermutability of Pa itself, with rapid development of resistant organisms and more difficult eradicating mucoid Pa phenotypes might account for eradication failure.
Conclusions
All the different studies on eradication treatment of the first ever colonization of Pa agree on the favorable effect of antibiotics on eradication of Pa, on the recurrence frequency of positive Pa cultures and on the delay in onset of chronic infection. Early treatment of Pa colonization/infection episodes is now considered the standard of care in CF centers. Recent studies have demonstrated that even mucoid Pa can be eradicated. Head-to-head comparison of different treatment regimens has until now been unable to define a superior treatment regimen. Larger head-to-head comparative studies are needed to determine the optimal treatment regimen and duration of eradication treatment. Ideally, every study on eradication treatment and those comparing treatment regimens should include genotypic characterization of Pa.
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.jcf.2012.07.008.
